An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of ...

The company said the weight loss and diabetes treatment drug failed to show any significant reduction in the progression of ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

Novo Nordisk’s closely-watched Alzheimer’s trials of an older oral version of its semaglutide drug failed to help slow the ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

Shares of Novo Nordisk (NVO) are down 10% and at their lowest level in four years after the pharmaceutical company said a ...

Novo Nordisk’s stock is experiencing a steep drop following major clinical setbacks and intensifying competitive pressure in ...